Since the first report on the efficacy of sextant biopsy under transrectal ultrasound guidance, there have been many modifications related to the total number of cores and the localization of biopsies to improve the prostate cancer (PCa) detection rate. The 2010 National Comprehensive Cancer Network Early PCa Detection Guidelines noted the 12-core biopsy scheme as the standard. However, this extended biopsy scheme still fails to detect 20% of high-grade PCa that can be detected by detailed pathological evaluation of radical prostatectomy; therefore, there is need for saturation biopsies. The existence of suspicions of PCa after previous negative biopsy or biopsies represents a valid indication for saturation biopsy. There has been no significant increment in morbidity or in insignificant PCa detection rates when a saturation biopsy scheme was used with an extended biopsy scheme. Along with the improvement in the PCa detection rate, accurate oncological mapping of PCa is another important consideration of saturation biopsies. The ideal number of cores and the diagnostic value of saturation biopsy after the failure of initial therapy are some of the issues that need to be addressed. Preliminary reports have shown that magnetic resonance imaging can improve the PCa detection rate, save patients from unnecessary biopsies, and decrease the need for a high number of cores; however, multiple limitations continue to exist
Purpose
To evaluate the relationship between levels of total testosterone and
total prostate-specific antigen (PSA) in healthy men with PSA<4 ng/mL.
Materials
and Methods
The study comprised 179 men with a mean age of 59.19±12 years who visited
Osmaniye State Hospital, Osmaniye, Turkey, between January 2006 and January
2007 for a routine checkup. The patients were divided into two subgroups:
patients with PSA<2.5 mg/ml (group I, n=160 patients) and patients with PSA
of 2.5 to 4 ng/mL (group II, n=19 patients). The relationship between PSA and
testosterone levels was investigated in both groups and in patients aged <60
years. The mean testosterone level was calculated for patients aged <50
years and was compared with the mean value of patients aged ≥50 years.
Results
In all patients, the mean values for serum PSA and total testosterone
were 1.27±0.88 ng/mL and 404.04±158.86 ng/mL, respectively. No correlation was
detected between serum PSA and testosterone levels in either subgroup (group I,
r=0.072, p=0.363; group II, r=0.031, p=0.900) or in patients aged <60 years
(r=0.032, p=0.72). The mean values of testosterone in patients aged ≥50 years
and in patients aged <50 years were 417.01±163.35 and 344.16±120.21 ng/dL,
respectively (p=0.02).
Conclusions
No impact of testosterone was found on the PSA level in healthy men with
PSA <4 ng/mL. Therefore, a high serum testosterone level may not mandate
adjustment of PSA values. This serum sex hormone showed a significant increment
after the age of 50 years. Further studies including a larger number of
patients should be carried out to confirm these findings
Locally recurrent prostate cancer after radiation therapy, also known as radiorecurrent prostate cancer, has an unfavorable prognosis. Two-thirds of patients with radiorecurrent prostate cancer have an advanced pathological disease status by the time they undergo salvage therapy. Several salvage therapies for radiorecurrent prostate cancer are available. Salvage radical prostatectomy (SRP) and salvage cryoablation are the most feasible and effective therapies for radiorecurrent prostate cancer. Although SRP is technically more difficult and has a higher complication rate than do other salvage therapies, the procedure provides a long-term survival benefit. Preliminary studies of salvage robot-assisted radical prostatectomy (SRARP) suggest that SRARP may be similar to or at least as effective as SRP. The intermediate oncological efficacy and morbidity of salvage cryoablation are similar to those of SRP. Prognostic factors for successful salvage therapy include serum prostate-specific antigen level ≤10 ng/mL, Gleason score ≤8, and a clinical disease stage T1c or T2. Assessing the comparative oncological efficacy and complications of the available salvage therapies for radiorecurrent prostate cancer requires strict guidelines, including universal patient selection criteria and an intergrade definition of biochemical failure.